Cargando…

Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system

The irradiation field of boron neutron capture therapy (BNCT) consists of multiple dose components including thermal, epithermal and fast neutron, and gamma. The objective of this work was to establish a methodology of dosimetric quality assurance (QA), using the most standard and reliable measureme...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirose, Katsumi, Kato, Takahiro, Harada, Takaomi, Motoyanagi, Tomoaki, Tanaka, Hiroki, Takeuchi, Akihiko, Kato, Ryohei, Komori, Shinya, Yamazaki, Yuhei, Arai, Kazuhiro, Kadoya, Noriyuki, Sato, Mariko, Takai, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303606/
https://www.ncbi.nlm.nih.gov/pubmed/35726375
http://dx.doi.org/10.1093/jrr/rrac030
_version_ 1784751908098932736
author Hirose, Katsumi
Kato, Takahiro
Harada, Takaomi
Motoyanagi, Tomoaki
Tanaka, Hiroki
Takeuchi, Akihiko
Kato, Ryohei
Komori, Shinya
Yamazaki, Yuhei
Arai, Kazuhiro
Kadoya, Noriyuki
Sato, Mariko
Takai, Yoshihiro
author_facet Hirose, Katsumi
Kato, Takahiro
Harada, Takaomi
Motoyanagi, Tomoaki
Tanaka, Hiroki
Takeuchi, Akihiko
Kato, Ryohei
Komori, Shinya
Yamazaki, Yuhei
Arai, Kazuhiro
Kadoya, Noriyuki
Sato, Mariko
Takai, Yoshihiro
author_sort Hirose, Katsumi
collection PubMed
description The irradiation field of boron neutron capture therapy (BNCT) consists of multiple dose components including thermal, epithermal and fast neutron, and gamma. The objective of this work was to establish a methodology of dosimetric quality assurance (QA), using the most standard and reliable measurement methods, and to determine tolerance level for each QA measurement for a commercially available accelerator-based BNCT system. In order to establish a system of dosimetric QA suitable for BNCT, the following steps were taken. First, standard measurement points based on tissue-administered doses in BNCT for brain tumors were defined, and clinical tolerances of dosimetric QA measurements were derived from the contribution to total tissue relative biological effectiveness factor-weighted dose for each dose component. Next, a QA program was proposed based on TG-142 and TG-198, and confirmed that it could be assessed whether constancy of each dose component was assured within the limits of tolerances or not by measurements of the proposed QA program. Finally, the validity of the BNCT QA program as an evaluation system was confirmed in a demonstration experiment for long-term measurement over 1 year. These results offer an easy, reliable QA method that is clinically applicable with dosimetric validity for the mixed irradiation field of accelerator-based BNCT.
format Online
Article
Text
id pubmed-9303606
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93036062022-07-22 Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system Hirose, Katsumi Kato, Takahiro Harada, Takaomi Motoyanagi, Tomoaki Tanaka, Hiroki Takeuchi, Akihiko Kato, Ryohei Komori, Shinya Yamazaki, Yuhei Arai, Kazuhiro Kadoya, Noriyuki Sato, Mariko Takai, Yoshihiro J Radiat Res Fundamental Radiation Science The irradiation field of boron neutron capture therapy (BNCT) consists of multiple dose components including thermal, epithermal and fast neutron, and gamma. The objective of this work was to establish a methodology of dosimetric quality assurance (QA), using the most standard and reliable measurement methods, and to determine tolerance level for each QA measurement for a commercially available accelerator-based BNCT system. In order to establish a system of dosimetric QA suitable for BNCT, the following steps were taken. First, standard measurement points based on tissue-administered doses in BNCT for brain tumors were defined, and clinical tolerances of dosimetric QA measurements were derived from the contribution to total tissue relative biological effectiveness factor-weighted dose for each dose component. Next, a QA program was proposed based on TG-142 and TG-198, and confirmed that it could be assessed whether constancy of each dose component was assured within the limits of tolerances or not by measurements of the proposed QA program. Finally, the validity of the BNCT QA program as an evaluation system was confirmed in a demonstration experiment for long-term measurement over 1 year. These results offer an easy, reliable QA method that is clinically applicable with dosimetric validity for the mixed irradiation field of accelerator-based BNCT. Oxford University Press 2022-06-20 /pmc/articles/PMC9303606/ /pubmed/35726375 http://dx.doi.org/10.1093/jrr/rrac030 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Fundamental Radiation Science
Hirose, Katsumi
Kato, Takahiro
Harada, Takaomi
Motoyanagi, Tomoaki
Tanaka, Hiroki
Takeuchi, Akihiko
Kato, Ryohei
Komori, Shinya
Yamazaki, Yuhei
Arai, Kazuhiro
Kadoya, Noriyuki
Sato, Mariko
Takai, Yoshihiro
Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system
title Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system
title_full Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system
title_fullStr Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system
title_full_unstemmed Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system
title_short Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system
title_sort determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system
topic Fundamental Radiation Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303606/
https://www.ncbi.nlm.nih.gov/pubmed/35726375
http://dx.doi.org/10.1093/jrr/rrac030
work_keys_str_mv AT hirosekatsumi determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT katotakahiro determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT haradatakaomi determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT motoyanagitomoaki determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT tanakahiroki determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT takeuchiakihiko determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT katoryohei determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT komorishinya determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT yamazakiyuhei determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT araikazuhiro determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT kadoyanoriyuki determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT satomariko determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem
AT takaiyoshihiro determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem